AI Article Synopsis
- Tacrolimus is a key immunosuppressive medication for kidney transplant patients, with two main prolonged-release options: Advagraf® and Envarsus®; however, they aren’t bioequivalent.
- A study was conducted to compare the safety and efficacy of Envarsus® and Advagraf® in 115 kidney transplant recipients, monitoring patient health over two years.
- The results showed no significant difference in patient survival or kidney function between the two formulations, but the LCPT group had a higher C/D ratio, and sepsis occurred more frequently in the Advagraf® group.
Article Abstract
Introduction: Calcineurin inhibitors constitute a cornerstone of immunosuppressive therapy in kidney transplant recipients. There are two main formulations of tacrolimus (Tac) which exhibit a prolonged-release mode of action: Advagraf® (MR-4) and Envarsus® (LCPT). However, they are not bioequivalent. Data comparing both once-daily prolonged-release formulations of Tac are insufficient.
Objective: The aim of the study was to compare safety and efficacy profiles of once-daily LCPT and MR-4 formulations of tacrolimus in adult kidney transplant recipients.
Patients And Methods: An observational, cohort single-center study was performed. One hundred fifteen kidney transplant recipients transplanted between 2016 and 2019 were enrolled to the study (59 vs 56, Envarsus® vs Advagraf®, respectively). Safety and efficacy profiles were assessed.
Results: Patient and graft survival at 12 and 24 months did not differ between the groups. There were no significant differences in serum creatinine at any timepoint. C/D ratio in the LCPT group was significantly higher at 12 and 24 months. Sepsis occurrence was more frequent in MR-4 group at 12 months.
Conclusion: Both prolonged-release formulations of tacrolimus are safe and effective in immunosuppressive therapy in kidney transplant recipients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858018 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0278894 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!